MRC1 and neoplasm: In other studies, there are also abnormalities or deletions of DNA mismatch repair (MMR) protein, indicating that deficient MMR (dMMR) may explain the hypermutation phenotype observed in tumor samples, which may provide a basis for immune checkpoint inhibitor therapy (8, 13, 14).